Psilocybin for Hallucinations
(PsilBlock1 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to assess the effects of 5-HT1A receptor blockade on the acute subjective effects of psilocybin, as measured through subjective survey measures and acute electroencephalography (EEG). Further, the investigators will assess the effects of psilocybin on post-acute sleep and dreaming through the use of sleep EEG and sleep and dream diaries.
Who Is on the Research Team?
Sandeep M Nayak, MD
Principal Investigator
Center for Psychedelics and Consciousness Research
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive psilocybin with either pindolol or placebo, with subjective and EEG assessments
Post-acute Monitoring
Participants complete sleep and dream diaries and wear a sleep EEG device
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Pindolol
- Psilocybin
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Psilocybin will be co-administered with 5-HT1A antagonist pindolol.
Psilocybin will be co-administered with microcrystalline cellulose placebo.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johns Hopkins University
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.